DDReg pharma

Quailty Driven by Passion

regulatory

Home » Blogs » regulatory
generative ai transforming life sciences drug discovery and development

Exploring the Future of Generative AI in Life Sciences

Generative Artificial Intelligence (Gen AI) has become a buzzword in the tech world, but its application goes far beyond creating content like text, images, and videos. While these creative applications are exciting, the real power of generative AI lies in its ability to generate entirely new data, models, and scientific insights transforming fields like life […]

Exploring the Future of Generative AI in Life Sciences Read More »

Generic drug registration and Approval process in Taiwan

Taiwan Generic Drug Registration Process

As global pharmaceutical companies intensify their focus on Asia-Pacific markets, Taiwan has emerged as a key strategic hub offering a stable regulatory environment, robust IP protection, and a high generic drug uptake under a universal healthcare system. Despite its relatively modest population, Taiwan punches above its weight in terms of healthcare spending and quality standards. 

Taiwan Generic Drug Registration Process Read More »

SAHPRA CTM lifecycle in South Africa

Navigating SAHPRA: A Guide for Complementary and Traditional Health Products in South Africa

Complementary and traditional health products are now subject to increasing regulatory oversight in South Africa, driven by SAHPRA’s evolving mandate. Once considered outside the formal regulatory scope, CTMs are now under increasing scrutiny by the South African Health Products Regulatory Authority (SAHPRA). This shift signals the government’s intent to ensure that all health-related products regardless

Navigating SAHPRA: A Guide for Complementary and Traditional Health Products in South Africa Read More »

GMP compliance for advanced therapies and biologics

GMP Compliance in the Era of Advanced Therapies and Biologics

The global biopharmaceutical industry is undergoing a transformative shift as advanced therapy medicinal products (ATMPs) including gene therapies, somatic cell therapies, and tissue-engineered products and complex biologics become central to innovation pipelines. According to a Report by ARM, as of Q2 2025, there are over 1,900 active CGT clinical trials, 2,070 developers, and $5.0 billion in

GMP Compliance in the Era of Advanced Therapies and Biologics Read More »

New Revolution with Multimedia and eConsent

Revolutionizing Informed Consent: Are Multimedia and eConsent the New Norm? 

Informed consent is a critical part of ethical clinical research, designed to ensure participants fully understand the nature, risks, and benefits of a trial before enrolling. However, for years, traditional paper-based consent processes have fallen short. Dense language, static formatting, and lack of personalization have made it difficult for many participants to grasp what they

Revolutionizing Informed Consent: Are Multimedia and eConsent the New Norm?  Read More »

Complete Guide to the Egypt Medical Device Registration Process

How to Register a Medical Device in Egypt: Regulatory Pathways with the EDA 

Egypt is fast emerging as a strategic healthcare hub in the MENA region, with a growing market for medical devices. For manufacturers looking to access this market, understanding the regulatory framework laid down by the Egyptian Drug Authority (EDA) is critical. Unlike the traditional pharmaceutical landscape, medical device registration in Egypt is governed by its

How to Register a Medical Device in Egypt: Regulatory Pathways with the EDA  Read More »

AI-Powered Regulatory Submissions in 2025

AI-Powered Regulatory Submissions: A New Era for IND, NDA, & BLA Documentation 

Regulatory submissions have always been the linchpin of drug development. From paper-based dossiers to the globally adopted electronic Common Technical Document (eCTD), the journey of regulatory documentation has continuously evolved. However, as life sciences companies contend with increasing data volumes, complex global regulatory requirements, and pressure to accelerate time-to-market, even eCTD processes are showing their

AI-Powered Regulatory Submissions: A New Era for IND, NDA, & BLA Documentation  Read More »

Types of vigilance in life science industry

Types of Vigilance Every Life Sciences Professional Should Know 

In the global life sciences industry, whether you’re launching a new pharmaceutical, a medical device, or a personal care product, the responsibility doesn’t end at regulatory approval. It extends across the product lifecycle, driven by a commitment to patient and consumer safety, and reinforced by an evolving web of global regulatory requirements.    Traditionally associated

Types of Vigilance Every Life Sciences Professional Should Know  Read More »

Current Trends in Advanced Therapies 2025

Breakthroughs in biotechnology are transforming how we approach some of the most challenging medical conditions. Genetic disorders, late-stage cancers, and severe tissue damage are increasingly being treated with therapies tailored to each individual’s unique biology. From gene therapies that rewrite faulty DNA to cell-based treatments that regenerate damaged tissue, advanced therapies are not just reshaping

Current Trends in Advanced Therapies 2025 Read More »

From Waste to Worth: Aligning Your Packaging Strategy with the EU PPWR

Imagine a world where every pill bottle, blister pack, and shipping box not only protects life-saving medications but also safeguards our planet. The PPWR, officially designated as Regulation (EU) 2024/1781, replaces the previous Packaging and Packaging Waste Directive 94/62/EC with a more harmonized approach to packaging sustainability. The EU PPWR Regulation officially entered into force on

From Waste to Worth: Aligning Your Packaging Strategy with the EU PPWR Read More »